CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALI

<p><strong>Background: </strong>Assessing clinical progression and CD4<sup>+</sup> level were important in determining the efficacy of antiretroviral (ARV) and switching to other regimens, especially when viral-load data were not available.   <sup> </sup>Thi...

Full description

Bibliographic Details
Main Authors: R. Niruri, A. A. S. Maharani, K. D. Kumara, and I. M. Rahajeng
Format: Article
Language:English
Published: DiscoverSys 2014-05-01
Series:Bali Medical Journal
Subjects:
Online Access:https://balimedicaljournal.org/index.php/bmj/article/view/77
id doaj-a2623324f794463390b6dcc9a8b823eb
record_format Article
spelling doaj-a2623324f794463390b6dcc9a8b823eb2020-11-25T03:54:33ZengDiscoverSysBali Medical Journal2089-11802302-29142014-05-013210.15562/bmj.v3i2.7776CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALIR. Niruri0A. A. S. Maharani1K. D. Kumara2and I. M. Rahajeng3Department of Pharmacy, Faculty of Mathematics and Sciences Udayana University, Bali-IndonesiaDepartment of Pharmacy, Faculty of Mathematics and Sciences Udayana University, Bali-IndonesiaDepartment of Pediatry, Sanglah General Hospital, Bali-IndonesiaFaculty of Medicine, Udayana University, Bali-Indonesia<p><strong>Background: </strong>Assessing clinical progression and CD4<sup>+</sup> level were important in determining the efficacy of antiretroviral (ARV) and switching to other regimens, especially when viral-load data were not available.   <sup> </sup>This research aims to assess combination of zidovudine-lamivudine-nevirapine (Co-ZLN) failure using  WHO 2010 criteria on clinical failure (CF) and immunological failure (IF), single or together, to determine correlation between CF and IF; and to evaluate two failure categories (CF alone and combination of CF-IF) in making decision to switch to second-line of ARV. <strong>Methods:</strong> Children at Sanglah General Hospital, who gain initial treatment of Co-ZLN in period of March 2006–March 2013 were selected. Cross-sectional study was applied. The ARV response was assessed twice. First period (P1) and second period (P2) of evaluation were conducted after patients received the Co-ZLN at least 6 and 12 months. <strong>Results:</strong> Forty five patients were included in this study. After at least 6 and 12 months of therapy, more patients showed IF (10 and 9 children in P1 and P2) than those in CF (4 and 2 patients in P1 and P2). Only one child met to CF-IF category in P2. The low clinical condition (HIV stage 4) did not always associate with deteriorating immunologic marker in the treatment-failure (TF). The patients who fit on CF and CF-IF based decision to switch regimen criteria were different. In resource-limited hospital, CF-IF based decision could give a better picture of patients’ condition and be used as an indicator to assess TF compared to single CF criteria.</p>https://balimedicaljournal.org/index.php/bmj/article/view/77first-line arv, failure, children
collection DOAJ
language English
format Article
sources DOAJ
author R. Niruri
A. A. S. Maharani
K. D. Kumara
and I. M. Rahajeng
spellingShingle R. Niruri
A. A. S. Maharani
K. D. Kumara
and I. M. Rahajeng
CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALI
Bali Medical Journal
first-line arv, failure, children
author_facet R. Niruri
A. A. S. Maharani
K. D. Kumara
and I. M. Rahajeng
author_sort R. Niruri
title CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALI
title_short CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALI
title_full CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALI
title_fullStr CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALI
title_full_unstemmed CLINICAL-IMMUNOLOGICAL ASSESSMENT FAILURE ON INITIAL COMBINATION USE OF ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE IN CHILDREN WITH HIV/AIDS AT SANGLAH HOSPITAL BALI
title_sort clinical-immunological assessment failure on initial combination use of zidovudine-lamivudine-nevirapine in children with hiv/aids at sanglah hospital bali
publisher DiscoverSys
series Bali Medical Journal
issn 2089-1180
2302-2914
publishDate 2014-05-01
description <p><strong>Background: </strong>Assessing clinical progression and CD4<sup>+</sup> level were important in determining the efficacy of antiretroviral (ARV) and switching to other regimens, especially when viral-load data were not available.   <sup> </sup>This research aims to assess combination of zidovudine-lamivudine-nevirapine (Co-ZLN) failure using  WHO 2010 criteria on clinical failure (CF) and immunological failure (IF), single or together, to determine correlation between CF and IF; and to evaluate two failure categories (CF alone and combination of CF-IF) in making decision to switch to second-line of ARV. <strong>Methods:</strong> Children at Sanglah General Hospital, who gain initial treatment of Co-ZLN in period of March 2006–March 2013 were selected. Cross-sectional study was applied. The ARV response was assessed twice. First period (P1) and second period (P2) of evaluation were conducted after patients received the Co-ZLN at least 6 and 12 months. <strong>Results:</strong> Forty five patients were included in this study. After at least 6 and 12 months of therapy, more patients showed IF (10 and 9 children in P1 and P2) than those in CF (4 and 2 patients in P1 and P2). Only one child met to CF-IF category in P2. The low clinical condition (HIV stage 4) did not always associate with deteriorating immunologic marker in the treatment-failure (TF). The patients who fit on CF and CF-IF based decision to switch regimen criteria were different. In resource-limited hospital, CF-IF based decision could give a better picture of patients’ condition and be used as an indicator to assess TF compared to single CF criteria.</p>
topic first-line arv, failure, children
url https://balimedicaljournal.org/index.php/bmj/article/view/77
work_keys_str_mv AT rniruri clinicalimmunologicalassessmentfailureoninitialcombinationuseofzidovudinelamivudinenevirapineinchildrenwithhivaidsatsanglahhospitalbali
AT aasmaharani clinicalimmunologicalassessmentfailureoninitialcombinationuseofzidovudinelamivudinenevirapineinchildrenwithhivaidsatsanglahhospitalbali
AT kdkumara clinicalimmunologicalassessmentfailureoninitialcombinationuseofzidovudinelamivudinenevirapineinchildrenwithhivaidsatsanglahhospitalbali
AT andimrahajeng clinicalimmunologicalassessmentfailureoninitialcombinationuseofzidovudinelamivudinenevirapineinchildrenwithhivaidsatsanglahhospitalbali
_version_ 1724473108495073280